ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.

Last updated: February 4, 2025
Sponsor: Dijklander Ziekenhuis
Overall Status: Terminated

Phase

4

Condition

Peripheral Vascular Disease

Coronary Artery Disease

Cardiovascular Disease

Treatment

ACT guided heparinization

5 000 IU of heparin

Clinical Study ID

NCT04061798
NL-66759
  • Ages > 18
  • All Genders

Study Summary

Aim of the ACTION-1 study is to determine whether ACT guided heparinization decreases thrombo-embolic complications (TEC) and mortality after elective open AAA surgery, without causing more bleeding complications.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Able to speak and read in local language of trial hospital.

  • Patients older than 18 years scheduled for elective, open repair of an iliac orabdominal aortic aneurysm distal of the Superior Mesenteric Artery (SMA) (DSAAsegment C).

  • Implantation of a tube or bifurcation prosthesis.

  • Trans-abdominal or retroperitoneal surgical approach of aneurysm.

  • Able and willing to provide written informed consent.

Exclusion

Exclusion Criteria:

  • Not able to provide written informed consent.

  • Previous open or endovascular intervention on the abdominal aorta (previous surgeryon other parts of the aorta or iliac arteries is not an exclusion criterion).

  • History of coagulation disorders, heparin induced thrombocytopenia (HIT), allergyfor heparin or thrombocyte pathology.

  • Impaired renal function with EGFR below 30 ml/min.

  • Acute open AAA surgery.

  • Hybrid interventions.

  • Connective tissue disorders.

  • Dual anti-platelet therapy, which cannot be discontinued.

  • Life expectancy less than 2 years.

  • Inflammatory, mycotic or infected aneurysms.

  • Allergy for protamine or fish protein

Study Design

Total Participants: 294
Treatment Group(s): 2
Primary Treatment: ACT guided heparinization
Phase: 4
Study Start date:
March 02, 2020
Estimated Completion Date:
April 29, 2024

Study Description

Heparin is used during open abdominal aortic aneurysm (AAA) surgery to reduce thrombo-embolic complications (TEC): such as myocardial infarction, stroke, peripheral embolic events and the related mortality. On the other hand, heparin may increase blood loss, causing harm for the patient.

Heparin has an unpredictable effect in the individual patient. The effect of heparin can be measured by using the Activated Clotting Time (ACT). ACT measurement in open AAA repair could be introduced to ensure the individual patient of safe, tailor-made anticoagulation with a goal ACT of 200-220 seconds. A randomized controlled trial (RCT) has to prove that ACT guided heparinization would result in fewer TEC and lower mortality than a standardized bolus of heparin of 5 000 international units (IU), the current gold standard. ACT guided heparinization results in higher doses of heparin during operation and this should not result in significantly more bleeding complications of importance.

The ACTION-1 study will evaluate the effect of weight dosed heparinization during open abdominal aortic aneurysm surgery.The study will be an international multi-centre single blind randomized controlled trial. Patients will be randomized using a computerized program (CASTOR EDC) with a random block size of a maximum of 8. The randomization will be stratified by participating centre. Separate evaluation of results and if complications can be labelled as TEC, will be performed by an Independent Central Adjudication Committee. The 3 members of this Committee will be blinded with regard to if the patient was randomized for ACT guided heparinization or standard bolus of 5 000 IU without ACT measurements.

In the intervention group, heparin is given to reach an ACT of 200-220 seconds. Based on the ACT, an additional dose of heparin will be administered. Five minutes after every administration of heparin the ACT is measured. If the ACT is 200 seconds or longer, the next ACT measurement is performed every 30 minutes, until the end of the procedure or until new heparin administration is required (because of ACT < 200 seconds). Depending on the ACT value near the end of surgery, protamine will be given to neutralize the effect of heparin.

In the comparative group, a single dose of 5 000 IU of heparin will be given 3-5 minutes before clamping of the aorta. No ACT measurements will be performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin.

Connect with a study center

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg,
    Germany

    Site Not Available

  • Krankenhaus Barmherzige Brüder

    Regensburg,
    Germany

    Site Not Available

  • Treant Zorggroep

    Emmen, Drenthe 7824AA
    Netherlands

    Site Not Available

  • Gelre Ziekenhuizen

    Apeldoorn, Gelderland 7334DZ
    Netherlands

    Site Not Available

  • Rijnstate

    Arnhem, Gelderland 6815 AD
    Netherlands

    Site Not Available

  • Slingeland Ziekenhuis

    Doetinchem, Gelderland 7009BL
    Netherlands

    Site Not Available

  • AUMC Location AMC

    Amsterdam, Noord Holland 1105AZ
    Netherlands

    Site Not Available

  • AUMC Location VUmc

    Amsterdam, Noord Holland 1081 HV
    Netherlands

    Site Not Available

  • Elisabeth TweeSteden Ziekenhuis

    Tilburg, Noord-Braband 5022 GC
    Netherlands

    Site Not Available

  • Amphia

    Breda, Noord-Brabant 4818 CK
    Netherlands

    Site Not Available

  • Catharina Ziekenhuis

    Eindhoven, Noord-Brabant 5623 EJ
    Netherlands

    Site Not Available

  • Dijklander Ziekenhuis

    Hoorn, Noord-Holland 1624NP
    Netherlands

    Site Not Available

  • Medisch Spectrum Twente

    Enschede, Overijssel 7512 KZ
    Netherlands

    Site Not Available

  • Isala

    Zwolle, Overijssel 8025 AB
    Netherlands

    Site Not Available

  • Haaglanden Medisch Centrum

    Den Haag, Zuid-Holland 2597AX
    Netherlands

    Site Not Available

  • Groene Hart

    Gouda, Zuid-Holland 2803 HH
    Netherlands

    Site Not Available

  • Leiden Universitair Medisch Centrum

    Leiden, Zuid-Holland 2333 ZA
    Netherlands

    Site Not Available

  • Alrijne

    Leiderdorp, Zuid-Holland 2353 GA
    Netherlands

    Site Not Available

  • Maasstad Ziekenhuis

    Rotterdam, Zuid-Holland 3079 DZ
    Netherlands

    Site Not Available

  • Ziekenhuisgroep Twente

    Almelo,
    Netherlands

    Site Not Available

  • Universitair Medisch Centrum Groningen

    Groningen,
    Netherlands

    Site Not Available

  • St. Antonius ziekenhuis

    Nieuwegein, 3435 CM
    Netherlands

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.